METHODS AND COMPOSITIONS USING LISTERIA FOR ADJUVANT TREATMENT OF CANCER

(19)

(11)

EP 2 576 791 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	21.12.2016 Bulletin 2016/51

(45)	Mention of the grant of the patent:
	19.10.2016 Bulletin 2016/42

(21)	Application number: 11787200.2

(22)	Date of filing: 23.05.2011

(51)

International Patent Classification (IPC):

C12N 15/75^(2006.01)

A61K 35/74^(2015.01)

(86)	International application number:
	PCT/US2011/037602

(87)	International publication number:
	WO 2011/149852 (01.12.2011 Gazette 2011/48)

(54)	METHODS AND COMPOSITIONS USING LISTERIA FOR ADJUVANT TREATMENT OF CANCER VERFAHREN UND ZUSAMMENSETZUNGEN MIT LISTERIA ZUR HILFSBEHANDLUNG VON KREBS PROCÉDÉS ET COMPOSITIONS UTILISANT LA LISTERIA POUR UN TRAITEMENT DU CANCER PAR ADJUVANT

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

23.05.2010 US 347447 P

(43)	Date of publication of application:
	10.04.2013 Bulletin 2013/15

(73)	Proprietor: Aduro BioTech, Inc.
	Berkeley, CA 94710 (US)

(72)	Inventors:
	DUBENSKY, Thomas, W. Piedmont, CA 94611 (US) BROCKSTEDT, Dirk, G. Richmond, CA 94804 (US) LEONG, Meredith Oakland, CA 94611 (US) BAHJAT, Keith, S. Portland, OR 97239 (US)

(74)	Representative: Brasnett, Adrian Hugh et al
	Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE City Tower 40 Basinghall Street London EC2V 5DE (GB)

(56)

References cited: :

WO-A1-2010/040135
US-A- 6 051 237

WO-A2-2008/094188
US-A1- 2007 207 171

S. H. KIM ET AL: "High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action", CANCER RESEARCH, vol. 69, no. 14, 15 July 2009 (2009-07-15) , pages 5860-5866, XP055080598, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-08-4855
HASSAN ET AL: "Mesothelin targeted cancer immunotherapy", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 44, no. 1, 22 October 2007 (2007-10-22), pages 46-53, XP022392314, ISSN: 0959-8049, DOI: 10.1016/J.EJCA.2007.08.028
D. T. LE ET AL: "A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction", CLINICAL CANCER RESEARCH, vol. 18, no. 3, 1 February 2012 (2012-02-01), pages 858-868, XP055080595, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-11-2121

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).